Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 22580.20 
• Atom Count: 1593 
• Residue Count: 198 
• Unique protein chains: 1

3GI6

Crystal structure of protease inhibitor, AD78 in complex with wild type HIV-1 protease

• DOI: 10.2210/pdb3GI6/pdb

• Classification: HYDROLASE/HYDROLASE INHIBITOR
• Organism(s): Human immunodeficiency virus type 1 group M subtype B
• Expression System: Escherichia coli
• Mutation(s): 1 


• Deposited: 2009-03-05 Released: 2010-03-09 
• Deposition Author(s): Nalam, M.N.L., Schiffer, C.A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.84 Å
• R-Value Free: 0.196 
• R-Value Work: 0.164 

Literature

Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.

Nalam, M.N., Ali, A., Altman, M.D., Reddy, G.S., Chellappan, S., Kairys, V., Ozen, A., Cao, H., Gilson, M.K., Tidor, B., Rana, T.M., Schiffer, C.A.

(2010) J.Virol. 84: 5368-5378

• PubMed: 20237088 
• DOI: 10.1128/JVI.02531-09
• Primary Citation of Related Structures:  
  3GI5, 3GI4


• PubMed Abstract: 
  

Drug resistance mutations in HIV-1 protease selectively alter inhibitor binding without significantly affecting substrate recognition and cleavage. This alteration in molecular recognition led us to develop the substrate-envelope hypothesis which predicts that HIV-1 protease inhibitors that fit within the overlapping consensus volume of the substrates are less likely to be susceptible to drug-resistant mutations, as a mutation impacting such inhibitors would simultaneously impact the processing of substrates. To evaluate this hypothesis, over 130 HIV-1 protease inhibitors were designed and synthesized using three different approaches with and without substrate-envelope constraints. A subset of 16 representative inhibitors with binding affinities to wild-type protease ranging from 58 nM to 0.8 pM was chosen for crystallographic analysis. The inhibitor-protease complexes revealed that tightly binding inhibitors (at the picomolar level of affinity) appear to "lock" into the protease active site by forming hydrogen bonds to particular active-site residues. Both this hydrogen bonding pattern and subtle variations in protein-ligand van der Waals interactions distinguish nanomolar from picomolar inhibitors. In general, inhibitors that fit within the substrate envelope, regardless of whether they are picomolar or nanomolar, have flatter profiles with respect to drug-resistant protease variants than inhibitors that protrude beyond the substrate envelope; this provides a strong rationale for incorporating substrate-envelope constraints into structure-based design strategies to develop new HIV-1 protease inhibitors.

---

Organizational Affiliation: 

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Protease	A, B	99	Human immunodeficiency virus type 1 group M subtype B	Mutation(s): 1  Gene Names: gag-pol
Find proteins for P03369 (Human immunodeficiency virus type 1 group M subtype B) Go to UniProtKB:  P03369

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
PO4	A, B	PHOSPHATE ION O4 P NBIIXXVUZAFLBC-UHFFFAOYSA-K
D78	A	(5S)-N-[(1S,2R)-2-Hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2-oxo-3-[3-(trifluoromethyl)phenyl]-5-oxazolidinecarboxamide (5S)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-{[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino}propyl]-2-oxo-3-[3-(trifluoromethyl)phenyl]-1,3-oxazolidine-5-carboxamide C32 H36 F3 N3 O7 S DDUYAVRQCCSESZ-NHKHRBQYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
D78	Ki: 0 nM (100) BINDINGDB
D78	Ki: 0.006 nM BINDINGMOAD
D78	Ki: 0.006 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.84 Å
• R-Value Free: 0.196 
• R-Value Work: 0.164 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length (Å)	Angle (°)
a = 50.803	α = 90.00
b = 58.021	β = 90.00
c = 61.671	γ = 90.00

Software Package:

Software Name	Purpose
REFMAC	refinement
DENZO	data reduction
AMoRE	phasing
SCALEPACK	data scaling
PDB_EXTRACT	data extraction

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2009-03-05 
• Released Date: 2010-03-09 
• Deposition Author(s): Nalam, M.N.L., Schiffer, C.A.

Revision History 

• Version 1.0: 2010-03-09
  Type: Initial release
• Version 1.1: 2011-07-13
  Type: Advisory, Refinement description, Version format compliance
• Version 1.2: 2017-11-01
  Type: Advisory, Refinement description